Intrauterine RBC Transfusion Dosage

Why use it

Untreated severe fetal anemia (MCA-PSV > 1.5 MoM) leads to fetal hydrops and death. IUT is a life-saving procedure. Precise dosing is critical — undertransfusion is ineffective, and overtransfusion risks fetal cardiac compromise from excessive polycythemia, increased blood viscosity, and acute volume overload. This calculator provides the target transfusion volume based on validated formulas.

About

Intrauterine transfusion (IUT) is the standard treatment for severe fetal anemia, most commonly due to red cell alloimmunization (Rh, Kell, Duffy, Kidd incompatibility) or fetal parvovirus B19 infection causing pure red cell aplasia. The procedure involves ultrasound-guided cordocentesis (intravascular IUT, preferred) or intraperitoneal transfusion. The volume of packed red blood cells (pRBCs) to transfuse is calculated to raise the fetal hematocrit to a target level (typically 40–50%) without overshoot. The formula uses the fetoplacental blood volume (FPV), estimated at approximately 140 mL/kg of estimated fetal weight (EFW) at mid-gestation, the pre-transfusion fetal hematocrit (obtained by cordocentesis), the donor pRBC hematocrit (typically 75–85% for washed, irradiated, CMV-negative, leukoreduced pRBCs), and the desired target hematocrit. The formula calculates the precise volume to transfuse to achieve the target hematocrit.

When to use

• Fetal anemia confirmed by cordocentesis (fetal Hct < 30% in non-hydropic; < 25–30% with hydrops)
• MCA-PSV > 1.5 MoM on Doppler ultrasound in a sensitized pregnancy
• Before intrauterine transfusion procedure to plan blood product volume
• Planning serial IUTs (typically every 2–4 weeks) in alloimmunized pregnancies
• Fetal parvovirus B19 with severe aplastic anemia (Hct < 20%)

Formula

Pearls & pitfalls

• Target post-transfusion Hct is typically 40–50%. Avoid Hct > 55% to prevent polycythemia and hyperviscosity syndrome.
• Fetoplacental blood volume (FPV) is approximately 140 mL/kg EFW at 20–24 weeks. Some sources use 120–150 mL/kg depending on gestational age.
• Donor RBC Hct must be measured — commercial pRBCs typically have Hct 55–80%. Washed and reconcentrated units may reach 75–85%.
• After the first IUT, subsequent transfusions may require larger volumes as fetal bone marrow suppression (from high transfused adult Hgb) reduces endogenous RBC production.
• After 2–3 IUTs, the fetal blood is predominantly donor (adult) RBCs — the MCA-PSV threshold for retransfusion must account for the different oxygen-carrying characteristics of adult vs. fetal hemoglobin.
• If intraperitoneal transfusion (IPT) is used (rarely, before 22 weeks when cordocentesis is technically difficult): volume = (gestational age - 20) × 10 mL per procedure.
• Kell alloimmunization suppresses fetal erythropoiesis MORE than the antibody titer suggests — MCA-PSV monitoring is mandatory regardless of titer.

Next steps

Obtain pre-transfusion fetal blood sample (cordocentesis) for Hct, blood type, direct Coombs, and CBC. Prepare irradiated, CMV-negative, leukoreduced, washed pRBCs (Hct 75–85%). Transfuse calculated volume via umbilical vein under continuous ultrasound guidance. Post-transfusion sampling confirms target Hct achieved. Schedule next IUT in 2–4 weeks (Hct typically falls 1% per day). After 34 weeks, delivery may be preferred over further IUT.

Evidence

Rodeck CH et al. The management of severe rhesus isoimmunization by fetoscopic intravascular transfusions. Am J Obstet Gynecol. 1984. Nicolaides KH et al. Cordocentesis in the investigation of fetal erythrocyte alloimmunization. BMJ. 1986;292(6525):919-922. Moise KJ. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008;112(1):164-176. PMID:18591322.

References

1. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008;112(1):164-176. — link
2. Nicolaides KH et al. Cordocentesis in the investigation of fetal erythrocyte alloimmunization. BMJ. 1986;292(6525):919-922. — link
3. Van Kamp IL et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol. 2005;192(1):171-177. — link